Who are Dasatinib Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DW6012(Dasidiem tab. 10/100mg), Nilotinib 300 mg., Radotinib HCl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dasatinib-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Dasatinib Tablets — Competitive Intelligence Brief

Dasatinib Tablets (Dasatinib Tablets) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BCR-ABL tyrosine kinase inhibitor. Area: Oncology.

marketed BCR-ABL tyrosine kinase inhibitor BCR-ABL, SRC family kinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dasatinib Tablets (Dasatinib Tablets) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dasatinib Tablets TARGET	Dasatinib Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
Nilotinib 300 mg.	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
Radotinib HCl	Radotinib HCl	Il-Yang Pharm. Co., Ltd.	phase 3	BCR-ABL tyrosine kinase inhibitor	BCR-ABL

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BCR-ABL tyrosine kinase inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Il-Yang Pharm. Co., Ltd. · 1 drug in this class
King Abdullah International Medical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dasatinib Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/dasatinib-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab